Ocugen logo
Ocugen OCGN
$ 1.84 -5.15%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Ocugen Balance Sheet 2011-2026 | OCGN

Annual Balance Sheet Ocugen

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-30.6 M -36.1 M -74.8 M -92.9 M -22 M -6.04 M -15.3 M -6.9 M -31.1 M -29.6 M -56.3 M -8.73 M -14.7 M -

Long Term Debt

27.3 M 2.8 M 2.29 M 1.71 M 1.82 M 1.07 M - - 178 K 761 K 1.34 M - - -

Long Term Debt Current

519 K 574 K 498 K 363 K 44.2 K 172 K - - - - - - - -

Total Non Current Liabilities

31.2 M 6.89 M 6.12 M 2.94 M 2.21 M 1.25 M 15 M 18.5 M 17.3 M 2.23 M 3.04 M 85.3 M 36.4 M -

Total Current Liabilities

21.6 M 17.1 M 28.5 M 7 M 3.61 M 4.54 M 14.1 M 3.8 M 5.17 M 6.36 M - - - -

Total Liabilities

52.8 M 24 M 34.7 M 9.94 M 5.83 M 5.79 M 17.9 M 22.3 M 22.5 M 8.59 M 11.3 M 90.4 M 40.8 M -

Retained Earnings

-340 M -286 M -223 M -132 M -73.3 M -51.5 M -217 M -208 M -182 M -166 M -134 M -111 M -85 M -

Total Assets

82.4 M 64.5 M 109 M 106 M 27.4 M 16.8 M 17.4 M 11 M 36.1 M 36.8 M 65.5 M 14.8 M 21 M -

Cash and Cash Equivalents

58.5 M 39.5 M 77.6 M 95 M 24 M 7.44 M 1.63 M 7.08 M 31.9 M 30.9 M 58.5 M - - -

Book Value

29.6 M 40.6 M 74 M 95.8 M 21.6 M 11 M -458 K -11.3 M 13.6 M 28.2 M 54.2 M -75.6 M -19.7 M -

Total Shareholders Equity

29.6 M 40.6 M 74 M 95.8 M 21.6 M 11 M -12.7 M 4.43 M 13.6 M 28.2 M 54.2 M - - -

All numbers in USD currency

Quarterly Balance Sheet Ocugen

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

28.4 M 28 M 27.7 M 27.3 M 1.57 M 1.55 M 1.53 M 2.8 M 1.5 M 1.47 M 1.06 M 2.29 M 2.26 M - 1.73 M 1.71 M 1.69 M 1.67 M 1.7 M 1.82 M 1.82 M 1.82 M 1.82 M 1.07 M 1.07 M 1.07 M 1.07 M 1.02 M 1.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

33.7 M 32.6 M 31.7 M 31.2 M 5.54 M 5.64 M 5.48 M 6.89 M 5.16 M 5.24 M 4.82 M 6.12 M 6.03 M - 2.91 M 2.94 M 2.97 M 3 M 3.08 M 2.21 M 2.21 M 2.21 M 2.21 M 1.25 M 1.25 M 1.25 M 1.25 M 1.05 M 1.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

54.1 M 50.5 M 48.5 M 52.8 M 21.3 M 23.6 M 21.5 M 24 M 16.3 M 18.7 M 20.5 M 24.6 M 20.9 M - 10.6 M 9.94 M 9.2 M 7.84 M 7.36 M 5.83 M 5.83 M 5.83 M 5.83 M 5.79 M 5.79 M 5.79 M 5.79 M 15.2 M 15.2 M 17.9 M 17.9 M 22.3 M 22.3 M 22.3 M 22.3 M 22.5 M 22.5 M 22.5 M 22.5 M 8.59 M 8.59 M 8.59 M 8.59 M 11.3 M 11.3 M 11.3 M 11.3 M - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 5 M 7.5 M 5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-390 M -370 M -356 M -340 M -326 M -313 M -298 M -286 M -267 M -252 M -230 M -213 M -191 M - -150 M -132 M -117 M -106 M -80.4 M -73.3 M -73.3 M -73.3 M -73.3 M -51.5 M -51.5 M -51.5 M -51.5 M 31.2 M -31.2 M -217 M -217 M -208 M -208 M -208 M -208 M -182 M -182 M -182 M -182 M -166 M -166 M -166 M -166 M -134 M -134 M -134 M -134 M - - - - - - - - - - - -

Total Assets

57.6 M 53.6 M 64.5 M 82.4 M 61.9 M 40.5 M 51.8 M 64.5 M 74.7 M 89 M 96.3 M 109 M 116 M - 142 M 106 M 116 M 124 M 53.8 M 27.4 M 27.4 M 27.4 M 27.4 M 16.8 M 16.8 M 16.8 M 16.8 M 2.45 M 2.45 M 17.4 M 17.4 M 11 M 11 M 11 M 11 M 36.1 M 36.1 M 36.1 M 36.1 M 36.8 M 36.8 M 36.8 M 36.8 M 65.5 M 65.5 M 65.5 M 65.5 M - - - - - - - - - - - -

Cash and Cash Equivalents

32.6 M 27 M 37.8 M 58.5 M 38.7 M 15.7 M 26.4 M 39.5 M 53.5 M 70.6 M 68.3 M 77.6 M 102 M 115 M 130 M 95 M 107 M 116 M 44.8 M 24 M 24 M 24 M 24 M 7.44 M 7.44 M 7.44 M 7.44 M 1.63 M 1.63 M 15.5 M 15.5 M 7.08 M 7.08 M 7.08 M 7.08 M 31.9 M 31.9 M 31.9 M 31.9 M 30.9 M 30.9 M 30.9 M 30.9 M 58.5 M 58.1 M 58.1 M 58.1 M 8.73 M - - - - - - - - - - -

Book Value

3.53 M 3.05 M 15.9 M 29.6 M 40.6 M 16.9 M 30.3 M 40.6 M 58.4 M 70.3 M 75.8 M 84.1 M 95.3 M - 131 M 95.8 M 107 M 116 M 46.5 M 21.6 M 21.6 M 21.6 M 21.6 M 11 M 11 M 11 M 11 M -12.7 M -12.7 M -458 K -458 K -11.3 M -11.3 M -11.3 M -11.3 M 13.6 M 13.6 M 13.6 M 13.6 M 28.2 M 28.2 M 28.2 M 28.2 M 54.2 M 54.2 M 54.2 M 54.2 M - - - - - - - - - - - -

Total Shareholders Equity

3.53 M 3.05 M 15.9 M 29.6 M 40.6 M 16.9 M 30.3 M 40.6 M 58.4 M 59.2 M 64.9 M 84.1 M 95.3 M 114 M 131 M 95.8 M 107 M 116 M 46.5 M 21.6 M 21.6 M 21.6 M 21.6 M 11 M 11 M 11 M 11 M -12.7 M -12.7 M -458 K -458 K 4.43 M -11.3 M -11.3 M -11.3 M 13.6 M 13.6 M 13.6 M 13.6 M 28.2 M 28.2 M 28.2 M 28.2 M 54.2 M 54.2 M 54.2 M 54.2 M -75.6 M - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Ocugen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.41 -1.4 % $ 2.57 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -6.51 % $ 4.31 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 165.07 -0.79 % $ 8.21 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.76 -1.7 % $ 1.12 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.57 -1.83 % $ 1.4 B britainBritain
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 18.11 1.23 % $ 870 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 26.36 -1.82 % $ 706 M usaUSA
Certara Certara
CERT
$ 7.24 2.62 % $ 1.16 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 1.01 -0.98 % $ 74.1 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.77 -0.46 % $ 2.91 B usaUSA
Agenus Agenus
AGEN
$ 3.27 -2.09 % $ 1.17 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 28.85 -1.2 % $ 1.67 B usaUSA
Champions Oncology Champions Oncology
CSBR
$ 5.98 -1.48 % $ 81.7 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.71 -2.43 % $ 116 M franceFrance
Alector Alector
ALEC
$ 2.13 -3.39 % $ 219 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 4.22 1.32 % $ 300 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.3 2.66 % $ 5.93 B irlandaIrlanda
AbbVie AbbVie
ABBV
$ 233.44 -0.33 % $ 413 B usaUSA